The pros and cons to using a dry powder inhaler as treatment for chronic obstructive pulmonary disease. Neil Minkoff, MD: Dr Drummond, we’ve talked a little bit about the differences. You brought some ...

Most people with asthma and other lung diseases have no idea that commonly prescribed inhalers are helping make the planet warmer. Each puff has about the same climate impact as driving a gas-powered ...

Miguel Divo shows his patient, Joel Rubinstein, a dry powder inhaler. It has a much lower carbon footprint than a traditional inhaler while being equally effective for many patients with asthma. Jesse ...

Switching from a metered dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...

Dr. Miguel Divo, a lung specialist at Brigham and Women’s Hospital, sits in an exam room, across from one of his patients with asthma. Joel Rubinstein, a retired psychiatrist, is about to get a ...

Background and Goal: This study examined whether patients with non-reversible chronic airway disease using a transparent capsule in single-dose dry powder inhalers affects the amount of medication ...

Dry Powder Inhalers (DPIs) are employed to supply a safe dose of Active Pharmaceutical Ingredient (API) to the deep lung. Image Credit: Freeman Technology An excipient transports the delicate ...

multiple inhalers on a white background Researchers explored the association between dry powder inhaler technique errors and exacerbations and health status in patients with COPD. Severe COPD ...

Switching from a metered-dose inhaler to a dry powder version for maintenance therapy more than halves the carbon footprint of people with asthma, and without any worsening of their condition, finds a ...

The Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, paying $2.5 million for a worldwide license with the same again to follow if it chooses to ...